CoChat
Sign Up
Cited by 455Atrial Fibrillation Management and OutcomesAcute Ischemic Stroke ManagementVenous Thromboembolism Diagnosis and Management

The DOI matches its Crossref record, with a small difference in title or year; 37 of the 38 references it cites were found in a registry or an index.

Net Clinical Benefit of Warfarin in Patients With Atrial Fibrillation: A Report From the Swedish Atrial Fibrillation Cohort Study

Open access
Friberg, Leif, Rosenqvist, Mårten, Lip, Gregory Y.H.·2012·Circulation
DOI 10.1161/circulationaha.111.055079
Open this paper in CoChat — free account

Abstract

Background—: Known risk factors for bleeding during anticoagulant treatment are largely the same as those predicting thromboembolic events in patients with atrial fibrillation (AF). Our objective was to investigate how to maximize the likelihood of avoiding both stroke and bleeding. Methods and Results—: All 182 678 subjects with atrial fibrillation in the Swedish Hospital Discharge Register were studied for an average of 1.5 years (260 000 patient-years at risk). Patients were stratified according to risk scores with the use of historic International Classification of Disease diagnostic codes in the register. Information about medication was obtained from the Swedish Drug Registry. Our primary end point was net benefit defined as number of avoided ischemic strokes with anticoagulation minus the number of excess intracranial bleedings with a weight of 1.5 to compensate for the generally more severe outcome with intracranial bleedings. The adjusted net clinical benefit favored anticoagulation for almost all atrial fibrillation patients. The exceptions were patients at very low risk of ischemic stroke with a CHA 2 DS 2 -VASc score of 0 and moderately elevated bleeding risk (−1.7%/y). The results were broadly similar with CHADS 2 , except for patients with very low embolic risk; the CHA 2 DS 2 -VASc was able to identify those patients (n=6205, 3.9% of all patients) who had no net clinical benefit or even some disadvantage from anticoagulant treatment. Conclusions—: In almost all patients with atrial fibrillation, the risk of ischemic stroke without anticoagulant treatment is higher than the risk of intracranial bleeding with anticoagulant treatment. Analysis of the net benefit indicates that more patients may benefit from anticoagulant treatment.

Overview

Integrity signals

Registry

Crossref · 10.1161/circulationaha.111.055079

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 38 references

Research works printed but not linked: 1

  1. 10.1001/archinte.1996.00440040081009 · DOI

Cited by

Sorted by citations

Items 401–455 of 455

Related

See all

Metadata

Authors
Friberg, L., Rosenqvist, M., & Lip, G. Y. H.
Affiliations
  • Birmingham City Hospital (GB)
  • Danderyds sjukhus (SE)
ORCID
Venue
Circulation
Publisher
Ovid Technologies (Wolters Kluwer Health)
Published
2012-05-15
Volume
125
Issue
19
Pages
2298-2307
ISSN
  • 0009-7322 (ISSN-L)
  • 1524-4539
DOI
10.1161/circulationaha.111.055079
OpenAlex
W2165762371
Cited by
454
References
38
Citations by year
2026: 9 · 2025: 15 · 2024: 9 · 2023: 14 · 2022: 16 · 2021: 28 · 2020: 31 · 2019: 33 · 2018: 26 · 2017: 30 · 2016: 57 · 2015: 50 · 2014: 54 · 2013: 57 · 2012: 24
FWCI
38.08
Type
journal article
Language
en
Open access
Licence
other-oa
Locations
  • Circulation (publishedVersion)
  • PubMed (publishedVersion)
  • University of Birmingham Research Portal (University of Birmingham) (submittedVersion, other-oa)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
  • Health Sciences › Medicine › Clinical Neurology › Acute Ischemic Stroke Management
  • Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
Keywords
atrial fibrillation, warfarin, anticoagulation, net clinical benefit, ischemic stroke, intracranial hemorrhage, CHA2DS2-VASc score, CHADS2 score, stroke risk stratification, bleeding risk, hospital discharge registry
MeSH terms
Aged, Anticoagulants, Atrial Fibrillation, Cerebral Hemorrhage, Female, Follow-Up Studies, Humans, Male, Middle Aged, Registries, Risk Factors, Sweden, Warfarin, Cohort Studies, Incidence, Stroke, Intracranial Embolism

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review